Please login to the form below

Not currently logged in
Email:
Password:

Galena starts registration for breast cancer vaccine trial

NeuVax aims to prevent recurrence in women ineligible for treatment with Roche’s Herceptin

Galena Biopharma has started a phase III trial of its breast cancer vaccine NeuVax with the aim of preventing recurrence in women who are not eligible for treatment with Roche's Herceptin.

The 700-patient study will enrol women with low or intermediate expression of the HER2 breast cancer biomarker, a group which accounts for around half of all breast cancer patients.

“These patients are successfully rendered disease-free following treatment with current standards of care, and are then sent home to watch and wait with the hope their cancer never returns,” said Beth Mittendorf of MD Anderson Cancer Center in the US, the principal investigator in the new trial.

Prior results from a phase I/II trial have suggested that NeuVax can “maintain disease-free survival in these patients who have no other [adjuvant treatment] options”, she added.

If successful, the new study – called PRESENT – could be sufficient in its own right to support marketing approval for NeuVax, according to Galena.

That could mean impressive returns for investors in the Oregon-based biotech, which currently has a market capitalisation of just $30m, according to analysts at Zacks Investment Research.

NeuVax could “easily” top $1bn in sales if it is approved for use in the 20,000 or so eligible breast cancer patients who are diagnosed each year in the US, the analysts added.

The company has also forged an alliance with Roche subsidiary Genentech to conduct a phase II study looking at the combination of NeuVax with Herceptin (trastuzumab) in 300 patients intermediate HER2 status patients who are currently not eligible for Herceptin treatment.

NeuVax consists of the E-75 peptide from the HER2/neu protein as an antigen, delivered alongside an immune stimulator (granulocyte macrophage colony-stimulating factor/GM-CSF). Galena acquired rights to the vaccine from the US military in July 2011.

24th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics